Advances in stem cell therapy for male stress urinary incontinence. (3rd April 2019)

• Record Type: Journal Article
• Authors: Gallo, Fabrizio; Ninotta, Gaetano; Schenone, Maurizio; Cortese, Pierluigi; Giberti, Claudio
• Is Part Of: Expert opinion on biological therapy. Volume 19:Number 4(2019)
• Page Start: 293
• Page End: 300
• Publication Date: 2019-04-03
• Subjects: Adult stem cell -- cell therapy -- complication -- postoperative -- injections -- mesenchymal stem cells -- prostatectomy -- regenerative medicine -- urinary incontinence -- stress; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2019.1578343
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Among the several options that have been proposed in recent years for the management of male stress urinary incontinence (SUI), stem cell therapy represents a new frontier in treatment. The aim of this paper is to update the current status of stem cell therapy in animal and human studies for the management of iatrogenic male SUI. Areas covered : A literature review was conducted based on MEDLINE/PubMed searches for English articles using a combination of the following keywords: stem cell therapy, urinary incontinence, prostatectomy, regenerative medicine, mesenchymal stem cells. Expert opinion : The few studies reported in the literature have demonstrated short-term safety and promising results of stem cell therapy in treating male SUI. However, many aspects need to be clarified before stem cell therapy can be introduced into daily urologic practice. In fact, important issues such as the limitations of these studies in terms of small sample sizes and short follow-ups, the incomplete knowledge of the mechanism of action of stem cells, the technical details regarding the delivery method and the best sources of stem cells, the safety risks regarding genomic or epigenetic changes and potential immune reactions in the longer term need to be identified in more stringent clinical trials.